ÈËÆÞÖгöÊÓƵ

Skip to main content
Matthew M. Poppe
( out of 40 reviews )

Matthew M. Poppe, MD, FASTRO

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
Salt Lake City
801-581-2396
  • Matthew Poppe, MD, a Huntsman Cancer Institute (HCI) physician and investigator, is a professor in the Department of Radiation Oncology at the ÈËÆÞÖгöÊÓƵ of Utah. He is a member of the multidisciplinary pediatric, sarcoma, and breast teams and is director of the residency program in Radiation Oncology.

    As the primary radiation oncologist providing radiation for kids with cancer, he is actively engaged in Children’s Oncology Group and conducts translational, clinical, and outcomes research. He works with the COG in the design of new pediatric clinical trials and is currently the radiation co-chair of AALL 1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.

    Dr. Poppe is actively engaged in the research and the care of patients with breast cancer. He currently serves as co-chair of the Breast Local Control group and Vice Chair for the Breast Committee for the Alliance Cooperative Trials Group and is a member of the NCI BOLD Task Force for the Breast Cancer Steering Committee. He is the principal investigator on an international trial (RT CHARM/Alliance A221505), which is a phase III randomized trial evaluating the safety and efficacy of short course radiation in the setting of mastectomy with breast reconstruction. He is also the principal investigator of a phase II trial at Huntsman Cancer Institute, evaluating a novel 9-day hypofractionated course of whole breast radiation. Additionally, he has published 34 peer-reviewed manuscripts, 3 book chapters, and presented numerous posters at national and international meetings. In 2018, he was recognized as a Huntsman Translational Scholar.

    Dr. Poppe earned a bachelor’s degree in mechanical engineering at Santa Clara ÈËÆÞÖгöÊÓƵ, Santa Clara, CA. He worked in engineering at NASA AMES before attending medical school at Oregon ÈËÆÞÖгöÊÓƵ Sciences ÈËÆÞÖгöÊÓƵ, Portland, OR. Dr. Poppe completed a Family Practice residency through the ÈËÆÞÖгöÊÓƵ of California Davis, Mercy Medical Center, Redding, California. In 2001, Dr. Poppe entered active duty in the US Air Force and practiced family and aerospace medicine until 2006. Dr. Poppe completed his radiation oncology residency at the Rutgers Cancer Institute of New Jersey. During residency, he was active in residency training issues as a review committee member for the Accreditation Council for Graduate Medical Education and Executive member of the Association of Residents in Radiation Oncology.

    Patient Rating

    4.8 /5
    ( out of 40 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 19, 2024
    HUNTSMAN CANCER CENTER

    Dr Poppe is easy to talk to, to present questions to and he¿s professional and kind. He actually looks me in the eye when he chats with me. He also isn¿t offended when I ask questions about radiation treatment options. Dr Poppe is the one I would refer my own daughter or son to for cancer treatment if the need ever arose.

    July 18, 2024
    HUNTSMAN CANCER CENTER

    Dr. Poppe is very friendly and professional. Answered all of my questions and addressed my concerns.

    July 12, 2024
    HUNTSMAN CANCER CENTER

    He¿s very professional, clear and knowledgeable. He also makes sure I understand what is going on. I would highly recommend him to anyone I know.

    July 11, 2024
    HUNTSMAN CANCER CENTER

    Very personable and professional.

    June 21, 2024
    HUNTSMAN CANCER CENTER

    Dr Poppe is one the kindest and most understanding Doctors I¿ve had the pleasure of being treated by! He listened to all of my concerns and questions that both me and my husband asked. If I ever need radiation, he will be the one that I go too.

    June 20, 2024
    HUNTSMAN CANCER CENTER

    Dr. Poppe recognized me as an individual, and worked with me as a collaborator regarding my treatment. He earned my trust, and I highly recommend his care.

    June 02, 2024
    SUGAR HOUSE HEALTH CENTER

    Very kind

    May 22, 2024
    HUNTSMAN CANCER CENTER

    Very kind and explains everything

    April 03, 2024
    HUNTSMAN CANCER CENTER

    Dr. Poppe is very aware of things going on and makes sure I know what is going on.

  • Matthew Poppe, MD, a Huntsman Cancer Institute (HCI) physician and investigator, is a professor in the Department of Radiation Oncology at the ÈËÆÞÖгöÊÓƵ of Utah. He is a member of the multidisciplinary pediatric, sarcoma, and breast teams and is director of the residency program in Radiation Oncology.

    As the primary radiation oncologist providing radiation for kids with cancer, he is actively engaged in Children’s Oncology Group and conducts translational, clinical, and outcomes research. He works with the COG in the design of new pediatric clinical trials and is currently the radiation co-chair of AALL 1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.

    Dr. Poppe is actively engaged in the research and the care of patients with breast cancer. He currently serves as co-chair of the Breast Local Control group and Vice Chair for the Breast Committee for the Alliance Cooperative Trials Group and is a member of the NCI BOLD Task Force for the Breast Cancer Steering Committee. He is the principal investigator on an international trial (RT CHARM/Alliance A221505), which is a phase III randomized trial evaluating the safety and efficacy of short course radiation in the setting of mastectomy with breast reconstruction. He is also the principal investigator of a phase II trial at Huntsman Cancer Institute, evaluating a novel 9-day hypofractionated course of whole breast radiation. Additionally, he has published 34 peer-reviewed manuscripts, 3 book chapters, and presented numerous posters at national and international meetings. In 2018, he was recognized as a Huntsman Translational Scholar.

    Dr. Poppe earned a bachelor’s degree in mechanical engineering at Santa Clara ÈËÆÞÖгöÊÓƵ, Santa Clara, CA. He worked in engineering at NASA AMES before attending medical school at Oregon ÈËÆÞÖгöÊÓƵ Sciences ÈËÆÞÖгöÊÓƵ, Portland, OR. Dr. Poppe completed a Family Practice residency through the ÈËÆÞÖгöÊÓƵ of California Davis, Mercy Medical Center, Redding, California. In 2001, Dr. Poppe entered active duty in the US Air Force and practiced family and aerospace medicine until 2006. Dr. Poppe completed his radiation oncology residency at the Rutgers Cancer Institute of New Jersey. During residency, he was active in residency training issues as a review committee member for the Accreditation Council for Graduate Medical Education and Executive member of the Association of Residents in Radiation Oncology.

    Board Certification and Academic Information

    Academic Departments Radiation Oncology -Primary

    Education history

    Residency Radiation Oncology - Robert Wood Johnson Hospital/UMDNJ Resident
    Family Practice - ÈËÆÞÖгöÊÓƵ of California Davis/Mercy Medical Center Resident
    Professional Medical Medicine - Oregon ÈËÆÞÖгöÊÓƵ Sciences ÈËÆÞÖгöÊÓƵ M.D.
    Mechanical Engineering - Santa Clara ÈËÆÞÖгöÊÓƵ B.S.

    Selected Publications

    Journal Article

    1. Zhao H, Sarkar V, St James S, Paxton A, Su FF, Price RG, Dial C, Poppe M, Gaffney D, Salter B (2024). Verification of surface-guided radiation therapy (SGRT) alignment for proton breast and chest wall patients by comparison to CT-on-rails and kV-2D alignment. J Appl Clin Med Phys, 25(2), e14263. ()
    2. Poppe MM, Tai A, Li XA, Miften M, Olch A, Marks LB, Qureshi BM, Spunt SL, Shnorhavorian M, Nelson G, Ronckers C, Kalapurakal J, Marples B, Constine LS, Liu AK (2023). Kidney Disease in Childhood Cancer Survivors Treated With Radiation Therapy: A Comprehensive PENTEC Genitourinary Review. Int J Radiat Oncol Biol Phys. ()
    3. Yashar C, Khan AJ, Chen P, Einck J, Poppe M, Li L, Yehia ZA, Vicini FA, Moore D, Arthur D, Quinn TJ, Kowzun M, Simon L, Scanderbeg D, Shah C, Haffty BG, Kuske R (2023). Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Interstitial Brachytherapy Is Safe: First Results From the Tri-fraction Radiation Therapy Used to Minimize Patient Hospital Trips (TRIUMPH-T) Trial. Pract Radiat Oncol, 13(4), 314-320. ()
    4. Berrington de Gonzlez A, Gibson TM, Lee C, Albert PS, Griffin KT, Kitahara CM, Liu D, Mille MM, Shin J, Bajaj BVM, Flood TE, Gallotto SL, Paganetti H, Ahmed SK, Eaton BR, Indelicato DJ, Milgrom SA, Palmer JD, Baliga S, Poppe MM, Tsang DS, Wong K, Yock TI (2023). The Pediatric Proton and Photon Therapy Comparison Cohort: Study Design for a Multicenter Retrospective Cohort to Investigate Subsequent Cancers After Pediatric Radiation Therapy. Adv Radiat Oncol, 8(6), 101273. ()
    5. von Mehren M, Kane JM, Riedel RF, Sicklick JK, Pollack SM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Poppe M, Schuetze S, Shabason J, Spraker MB, Zimel M, Bergman MA, Sundar H, Hang LE (2022). NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. J Natl Compr Canc Netw, 20(11), 1204-1214. ()
    6. Tao R, Chen Y, Kim S, Ocier K, Lloyd S, Poppe MM, Lee CJ, Glenn MJ, Smith KR, Fraser A, Deshmukh V, Newman MG, Snyder J, Rowe KG, Gaffney DK, Haaland B, Hashibe M (2022). Mental health disorders are more common in patients with Hodgkin lymphoma and may negatively impact overall survival. Cancer, 128(19), 3564-3572. ()
    7. von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Pollack SM, Poppe M, Riedel RF, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Hang LE, Sundar H, Bergman MA (2022). Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(7), 815-833. ()
    8. Peterson JS, Peckham ME, Poppe MM, Burt LS, Shrieve DC, Cannon DM (2022). Delineating the Subarachnoid Space in the Adult Lumbosacral Spine Using Computed Tomographic Myelography: An Aid for Clinical Target Volume Delineation in Craniospinal Irradiation. Adv Radiat Oncol, 7(5), 100994. ()
    9. Weil CR, Lew FH, Williams VM, Burt LM, Ermoian RP, Poppe MM (2022). Patterns of Care and Utilization Disparities in Proton Radiation Therapy for Pediatric Central Nervous System Malignancies. Adv Radiat Oncol, 7(6), 100868. ()
    10. Weiss A, Campbell J, Ballman KV, Sikov WM, Carey LA, Hwang ES, Poppe MM, Partridge AH, Ollila DW, Golshan M (2021). Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Ann Surg Oncol, 28(11), 5960-5971. ()
    11. Parsons MW, Whipple NS, Poppe MM, Mendez JS, Cannon DM, Burt LM (2020). The use and efficacy of chemotherapy and radiotherapy in ÈËÆÞÖгöÊÓƵren and adults with pilocytic astrocytoma. J Neurooncol, 151(2), 93-101. ()
    12. von Mehren M, Kane JM, Bui MM, Choy E, Connelly M, Dry S, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Meyer C, Pappo AS, Parkes AM, Paz IB, Petersen IA, Poppe M, Riedel RF, Rubin B, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Bergman MA, George GV (2020). NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw, 18(12), 1604-1612.
    13. Hendrickson PG, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop AJ, Lloyd S, Kokeny KE, Hitchcock YJ, Poppe MM, Gaffney DK, Tao R (2020). Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study. Cancer Med, 9(21), 7954-7963. ()
    14. Poppe MM, Yehia ZA, Baker C, Goyal S, Toppmeyer D, Kirstein L, Chen C, Moore DF, Haffty BG, Khan AJ (2020). 5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial. Int J Radiat Oncol Biol Phys, 107(4), 694-700. ()
    15. Lucas CG, Villanueva-Meyer JE, Whipple N, Oberheim Bush NA, Cooney T, Chang S, McDermott M, Berger M, Cham E, Sun PP, Putnam A, Zhou H, Bollo R, Cheshier S, Poppe MM, Fung KM, Sung S, Glenn C, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Alva E, Johnston J, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon DA (2020). Myxoid Glioneuronal Tumor, PDGFRA p.K385-mutant: Clinical, Radiologic, and Histopathologic Features. Brain Pathol, 30(3), 479-494.
    16. Lucas CG, Villanueva-Meyer JE, Whipple N, Oberheim Bush NA, Cooney T, Chang S, McDermott M, Berger M, Cham E, Sun PP, Putnam A, Zhou H, Bollo R, Cheshier S, Poppe MM, Fung KM, Sung S, Glenn C, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Alva E, Johnston J, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon DA (2019). Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain Pathol, 30(3), 479-494. ()
    17. Wells S, Ager B, Hitchcock YJ, Poppe MM (2019). The radiation dose-response of non-retroperitoneal soft tissue sarcoma with positive margins: An NCDB analysis. J Surg Oncol, 120(8), 1476-1485. ()
    18. Boothe D, Orton A, Kim J, Poppe MM, Werner TL, Gaffney DK (2019). Does Early Chemotherapy Improve Survival in Advanced Endometrial Cancer? Am J Clin Oncol, 42(11), 813-817. ()
    19. Zhao H, Williams N, Poppe M, Sarkar V, Wang B, Rassiah-szegedi P, Huang JY, Kokeny K, Gaffney D, Salter B (2019). Comparison of surfacing matching and target matching for image guided accelerated partial breast irradiation (APBI). Med Phys, 46(11), 4717-4724.
    20. Ager BJ, Christensen MT, Burt LM, Poppe MM (2019). The value of high-dose radiotherapy in intracranial ependymoma. Pediatr Blood Cancer, 66(6), e27697. ()
    21. Khan AJ, Chen PY, Yashar C, Poppe MM, Li L, Abou Yehia Z, Vicini FA, Moore D, Dale R, Arthur D, Shah C, Haffty BG, Kuske R (2019). Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered With Brachytherapy Applicators Is Feasible and Safe: First Results From the TRIUMPH-T Trial. . Int J Radiat Oncol Biol Phys, 104(1), 67-74.
    22. Tward JD, Poppe MM, Hitchcock YJ, ONeil B, Albertson DJ, Shrieve DC (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med, 7(12), 6030-6039. ()
    23. Frandsen JE, Cannon G, Kokeny KE, Gaffney DK, Matsen C, Wright M, Poppe MM (2018). Is radiation indicated for young women with early stage, node-negative breast cancer after mastectomy? A multi-institution, retrospective review. Breast J, 24(1), 7-11. ()
    24. Huang YJ, Su FF, Gaffney DK, Kokeny KE, Zhao H, Rassiah-Szegedi P, Salter BJ, Poppe MM (2018). Skin dose estimation using virtual structures for Contura Multi-Lumen Balloon breast brachytherapy. Brachytherapy, 17(6), 956-965. ()
    25. Torgeson A, Boothe D, Poppe MM, Suneja G, Gaffney DK (2017). Disparities in care for elderly women with endometrial cancer adversely effects survival. Gynecol Oncol, 147(2), 320-328. ()
    26. Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK (2017). Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast, 35, 122-129. ()
    27. Frandsen J, Cannon G, Kokeny KE, Gaffney DK, Wright M, Pena K, Poppe MM (2017). Post-mastectomy Radiotherapy for pT3N0 Breast Cancers: A Retrospective, Multi-Institution Review. Breast J, 23(4), 452-455. ()
    28. Khan AJ, Poppe MM, Goyal S, Kokeny KE, Kearney T, Kirstein L, Toppmeyer D, Moore DF, Chen C, Gaffney DK, Haffty BG (2017). Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial. J Clin Oncol, 35(18), 2037-2043. ()
    29. Boothe D, Williams N, Odei B, Poppe MM, Werner TL, Suneja G, Gaffney DK (2017). The Addition of Adjuvant Chemotherapy to Radiation in Early-Stage High-Risk Endometrial Cancer: Survival Outcomes and Patterns of Care. Int J Gynecol Cancer, 27(5), 912-922. ()
    30. Bingham B, Orton A, Boothe D, Stoddard G, Huang YJ, Gaffney DK, Poppe MM (2017). Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement. Int J Radiat Oncol Biol Phys, 97(5), 1040-1050. ()
    31. Francis SR, Frandsen J, Kokeny KE, Gaffney DK, Poppe MM (2017). Outcomes and utilization of postmastectomy radiotherapy for T3N0 breast cancers. Breast, 32, 156-161. ()
    32. Odei B, Boothe D, Suneja G, Werner TL, Poppe MM, Gaffney DK (1/24/2017). Chemoradiation versus chemotherapy in Uterine Carcinosarcoma: patterns of care and impact on overall survival. Am J Clin Oncol.
    33. Odei B, Frandsen JE, Boothe D, Ermoian RP, Poppe MM (2017). Patterns of Care in Proton Radiation Therapy for Pediatric Central Nervous System Malignancies. Int J Radiat Oncol Biol Phys, 97(1), 60-63. ()
    34. Boothe D, Orton A, Odei B, Stoddard G, Suneja G, Poppe MM, L Werner T, Gaffney DK (2016). Corrigendum to "Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival" [Gynecol. Oncol. 141 (2016) 421-427]. Gynecol Oncol, 143(3), 690-691. ()
    35. Burt L, Poppe MM, Kokeny KE, Gaffney DK, Shrieve DC, Tward JD (8/1/2016). Comparison of treatment modalities for breast cancer arising in Hodgkin’s lymphoma survivors. J Radiat Oncol.
    36. Boothe D, Orton A, Odei B, Stoddard G, Suneja G, Poppe MM, Werner TL, Gaffney DK (2016). Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival. Gynecol Oncol, 141(3), 421-427. ()
    37. Orton A, Boothe D, Williams N, Buchmiller T, Huang YJ, Suneja G, Poppe MM, Gaffney DK (04/01/2016). Brachytherapy Improves Survival in Primary Vaginal Cancer. Gynecol Oncol, 141(3), 501-6.
    38. Ahmed F, Sarkar V, Gaffney DK, Salter B, Poppe MM (2016). Analysis of nodal coverage utilizing image guided radiation therapy for primary gynecologic tumor volumes. Med Dosim, 41(3), 195-8. ()
    39. Frandsen J, Ly D, Cannon G, Suneja G, Matsen C, Gaffney DK, Wright M, Kokeny KE, Poppe MM (2015). In the Modern Treatment Era, Is Breast Conservation Equivalent to Mastectomy in Women Younger Than 40 Years of Age? A Multi-Institution Study. Int J Radiat Oncol Biol Phys, 93(5), 1096-103. ()
    40. Frandsen JE, Wagner A, Bollo RJ, Shrieve DC, Poppe MM (2015). Long-term life expectancy for ÈËÆÞÖгöÊÓƵren with ependymoma and medulloblastoma. Pediatr Blood Cancer, 62(11), 1986-91. ()
    41. Mazur MD, Ravindra VM, Alashari M, Raetz E, Poppe MM, Bollo RJ (2015). Primary T cell central nervous system lymphoblastic lymphoma in a ÈËÆÞÖгöÊÓƵ: case report and literature review. Childs Nerv Syst, 31(6), 977-84. ()
    42. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H, National comprehensive cancer network (2/01/2015). Hodgkin Lymphoma, Version 2.2015. J Natl Compr Canc Netw, 13(5), 554-586.
    43. Badiyan SN, Shah C, Arthur D, Khan AJ, Freedman G, Poppe MM, Vicini FA (2014). Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies. Radiother Oncol, 110(1), 39-44. ()
    44. Tunceroglu A, Park JH, Balasubramanian S, Poppe M, Anker CJ, Poplin E, Moss RA, Yue NJ, Carpizo D, Gannon CJ, Haffty BG, Jabbour SK (10/18/2012). Dose-Painted Intensity Modulated Radiation Therapy Improves Local Control for Locally Advanced Pancreas Cancer. ISRN Oncol, 2012, 572342.
    45. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H (5/10/2012). Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw, 10(5), 589-97.
    46. Gondi V, Bernard JR Jr, Jabbari S, Keam J, de Amorim Bernstein KL, Dad LK, Li L, Poppe MM, Strauss JB, Chollet CT, ARRO Executive Committee (2012). Results of the 2005 to 2008 Association of Residents in Radiation Oncology surveys of chief residents in the United States: didactics and research experience. Am J Clin Oncol, 35(1), 32-9. ()
    47. Gondi V, Bernard JR Jr, Jabbari S, Keam J, de Amorim Bernstein KL, Dad LK, Li L, Poppe MM, Strauss JB, Chollet CT, ARRO Executive Committee (2011). Results of the 2005-2008 Association of Residents in Radiation Oncology survey of chief residents in the United States: clinical training and resident working conditions. Int J Radiat Oncol Biol Phys, 81(4), 1120-7. ()
    48. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J (9/01/2011). Hodgkin Lymphoma. J Natl Compr Canc Netw, 9(9), 1020-58.
    49. Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, Alexander R, Hanna N, Regine WF (Jan 2011). Intensity-Modulated Radiation Therapy (IMRT) Significantly Improves Acute Gastrointestinal Toxicity in Pancreatic and Ampullary Cancers. Int J Radiat Oncol Biol Phys, 79(1), 158-162.
    50. Poppe MM, Narra V, Yue NJ, Zhou J, Nelson C, Jabbour SK (2011). A comparison of helical intensity-modulated radiotherapy, intensity-modulated radiotherapy, and 3D-conformal radiation therapy for pancreatic cancer. Med Dosim, 36(4), 351-7. ()
    51. Zhao H, Wang B, Rassiah-Szegedi P, Huang Y, Sarkar V, Szegedi M, Sadinski M, Kokeny K, Poppe M, Salter B (1/1/2011). SU-E-T-527: Comparison of CT-On-Rails and a 3D Surface Imaging System for Image Guided Partial Breast Radiation Therapy. Med Phys, 38(6), 3610.

    Review

    1. Aridgides P, Janssens GO, Braunstein S, Campbell S, Poppe M, Murphy E, MacDonald S, Ladra M, Alapetite C, Haas-Kogan D (2020). Gliomas, germ cell tumors, and craniopharyngioma. [Review]. Pediatr Blood Cancer, 68 Suppl 2, e28401. ()
    2. Chang JH, Poppe MM, Hua CH, Marcus KJ, Esiashvili N (2020). Acute lymphoblastic leukemia. [Review]. Pediatr Blood Cancer, 68 Suppl 2, e28371. ()
    3. Poppe MM, Agarwal JP (2017). Breast Reconstruction With Postmastectomy Radiation: Choices and Tradeoffs. [Review]. J Clin Oncol, 35(22), 2467-2470. ()

    Book Chapter

    1. Poppe MM, Jalali R, Murphy E (2018). Pediatric Glioma. In Merchant, T, Kortmann, R (Eds.), Pediatric Radiation Oncology (1, pp. 171-202). Springer.
    2. Poppe MM, Shah, C, Khan, A (2016). Hypofractionated Regional Nodal Irradiation for Breast Cancer. In Arthur, D; Vicini, V; Wazer, D; Khan, A. (Eds.), Short Course Breast Radiotherapy: A comprehensive review of hypofractionation, partial breast, and intra-operative irradiation (1st, pp. 441-466). Springer.
    3. Poppe MM, Blodgett TM (07/30/2012). Kidney. In David Gaffney (Ed.), Radiation Oncology: Imaging and Treatment (1st). Amirsys.
    4. Poppe MM, Gaffney DK (07/30/2012). Adrenal Gland. In David Gaffney (Ed.), Radiation Oncology: Imaging and Treatment (1st). Amirsys.

    Letter

    1. Poppe MM, Khan AJ (2020). In Reply to Dyer et al. [Letter to the editor]. Int J Radiat Oncol Biol Phys, 109(1), 301-302. ()
    2. Meyer JE, Dilling TJ, Amdur RJ, Strasser JF, Tendulkar R, Lee WR, Jani AB, Elshaikh M, Poppe MM, Takita C, Currey A, Cheng SK, Jagsi R, Kuo JV, Chen AM, Dragun AE, Bradley K, Beriwal S, Smith RP, Chen RC, Rosenzweig K, Kim S, Mehta K (03/15/2016). In regard to Wu and Vapiwala et al., Taking “the Game” Out of The Match: A Simple Proposal [Letter to the editor]. Int J Radiat Oncol Biol Phys, 94(5), 858-9.
    3. Meyer JE, Dilling TJ, Amdur RJ, Strasser JF, Tendulkar R, Lee WR, Jani AB, Elshaikh M, Poppe MM, Takita C, Currey A, Cheng SK, Jagsi R, Kuo JV, Chen AM, Dragun AE, Bradley K, Beriwal S, Smith RP, Chen RC, Rosenzweig K, Kim S, Mehta K (2016). In regard to Wu and Vapiwala et al. [Letter to the editor]. Int J Radiat Oncol Biol Phys, 94(4), 858-9. ()

    Abstract

    1. Bagshaw H, Poppe MM, Hunter G (9/25/2016). Recurrent Medulloblastoma and Radiotherapy [Abstract]. Int j Radiat Oncol Biol phys, 96(S2), 553.